Webcast description
This episode of EASL’s webcast series on COVID-19 and the liver examines the impact of the virus on patients with obesity and fatty liver disease. The panel of experts comprises Professor Sven Francque, Professor Nalu Navarro-Alvarez, Professor Luca Busetto and Professor Carolyn Bramante. Professor Busetto begins by reviewing prevalence data on COVID-19 in people with obesity or metabolic syndrome, drawing from Italian and global experiences, and describes the biological mechanisms behind increased COVID-19 severity in these populations. Professor Bramante reports on research linking fatty liver disease with severe COVID-19 and the potential for some medications to be protective against hospitalization in these patients. Professor Navarro-Alvarez describes the mechanisms behind the elevated risk of COVID-19 and the impact of metabolic syndrome. The panel addresses several aspects including the importance of visceral adiposity and systemic inflammation.
Moderator: Prof. Sven Francque
Panel:
• Prof. Luca Busetto
• Prof. Carolyn Bramante
• Prof. Nalu Navarro-Alvarez
Learning objectives
- Learn about the prevalence of COVID-19 in people with obesity or fatty liver disease
- Understand the mechanisms behind the elevated risk of COVID-19 and the impact of metabolic syndrome
- Learn about medications that might prevent hospitalization of patient with fatty liver disease and severe COVID-19
- Learn how the visceral adiposity and systemic inflammation impact COVID-19 severity
Target audience
- Hepatologists
- General practitioners
- Health care professionals
- Clinical researchers and scientists